Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper

Blood (2022) 140 (Supplement 1): 6102–6103.

https://doi.org/10.1182/blood-2022-163503

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A. Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L Brooks, Tariq I. Mughal, Andrew A. Lane

Blood (2021) 138 (Supplement 1): 874.

https://doi.org/10.1182/blood-2021-145109

Published: 2021

Journal Articles

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Ayalew Tefferi, Christopher L Brooks, Guillermo Garcia-Manero, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 538.

https://doi.org/10.1182/blood-2021-147827

Published: 2021

Journal Articles

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Arghya Ray, Clifton C. Mo, Ting DU, Arturo Olguin, Janice Chen, Christopher L Brooks, Tariq I. Mughal, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2021-153458

Published: 2021

Journal Articles

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

Andrew A. Lane, Anthony S. Stein, Jacqueline S. Garcia, Jada L. Garzon, Ilene Galinsky, Marlise R. Luskin, Richard M. Stone, Eric S. Winer, Rebecca Leonard, Tariq I. Mughal, Christopher L Brooks, Marina Konopleva, Kristen E. Stevenson, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2021-147486

Published: 2021

Journal Articles

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Abdulraheem Yacoub, Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Vikas Gupta, Sangmin Lee, Gary J. Schiller, Minakshi S. Taparia, Animesh Pardanani, Ayalew Tefferi, Srdan Verstovsek, Joseph D. Khoury, Christopher L Brooks, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 140.

https://doi.org/10.1182/blood-2021-145276

Published: 2021

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Hematopoietic and Microglia Recovery and Disease Correction in a Mouse Model of Hurler Syndrome

Kevin A. Goncalves, PhD, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Hans J. Hertzler, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2019) 134 (Supplement_1): 4424.

https://doi.org/10.1182/blood-2019-131189

Published: 2019

Journal Articles

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

Geoff O Gillard, Jennifer L Proctor, BS, Melissa L. Brooks, BS, Tahirih L Lamothe, BS, Sharon L. Hyzy, MS, Oliver Mikse, Sean McDonough, Rahul Palchaudhuri, PhD, Anjali Bhat, MS, Ganapathy N. Sarma, PhD, Prashant Bhattarai, Pranoti Sawant, MS, Bradley R Pearse, PhD, Charlotte F. Mcdonough, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2019) 134 (Supplement_1): 3208.

https://doi.org/10.1182/blood-2019-130752

Published: 2019

Journal Articles

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Bradley R Pearse, PhD, Sean M McDonough, MS, Jennifer L Proctor, BS, Rajiv Panwar, PhD, Ganapathy Sarma, PhD, Molly A McShea, MS, Lena Kien, BS, Junia Dushime, BS, Hillary L Adams, MS, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Rahul Palchaudhuri, PhD, Qing Li, PhD, Nathan M Kallen, BA, Pranoti Sawant, MS, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2018-99-114881

Published: 2018

Journal Articles

Single Doses of Antibody Drug Conjugates (ADCs) Targeted to CD117 or CD45 Have Potent In Vivo Anti-Leukemia Activity and Survival Benefit in Patient Derived AML Models

Blood (2018) 132 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2018-99-112726

Published: 2018

Journal Articles

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Blood (2018) 132 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2018-99-117167

Published: 2018

Journal Articles

MGTA-456, a First-in-Class Cell Therapy Produced from a Single Cord Blood Unit, Enables a Reduced Intensity Conditioning Regimen and Enhances Speed and Level of Human Microglia Engraftment in the Brains of NSG Mice

Kevin A. Goncalves, PhD, Shuping Li, PhD, Melissa L. Brooks, BS, Sharon L. Hyzy, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 115.

https://doi.org/10.1182/blood-2018-99-118258

Published: 2018

Journal Articles

Antibody Drug Conjugates Targeted to CD45 or CD117 Enable Allogeneic Hematopoietic Stem Cell Transplantation in Animal Models

Rahul Palchaudhuri, PhD, Sharon L. Hyzy, MS, Jennifer L Proctor, BS, Hillary L Adams, MS, Bradley R Pearse, PhD, Ganapathy Sarma, PhD, Sharon Aslanian, MS, Geoff Gillard, PhD, Tahirih L Lamothe, Olga Burenkova, BS, Melissa L. Brooks, BS, Andrew D Gabros, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3324.

https://doi.org/10.1182/blood-2018-99-119432

Published: 2018

Journal Articles

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Deepika Sharma Das, PhD, Vincent Macri, MA, Janice Chen, PhD, Claudia Paba-Praba, Paul G. Richardson, MD, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4463.

https://doi.org/10.1182/blood.V128.22.4463.4463

Published: 2016

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

John Gionco, Janice Chen, PhD, Ross Lindsay, PhD, Vince Macri, M.A., Christopher L. Brooks, PhD

Blood (2016) 128 (22): 4724.

https://doi.org/10.1182/blood.V128.22.4724.4724

Published: 2016

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Blood (2016) 128 (22): 215.

https://doi.org/10.1182/blood.V128.22.215.215

Published: 2016

NARROW

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Hematopoietic and Microglia Recovery and Disease Correction in a Mouse Model of Hurler Syndrome

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Single Doses of Antibody Drug Conjugates (ADCs) Targeted to CD117 or CD45 Have Potent In Vivo Anti-Leukemia Activity and Survival Benefit in Patient Derived AML Models

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

MGTA-456, a First-in-Class Cell Therapy Produced from a Single Cord Blood Unit, Enables a Reduced Intensity Conditioning Regimen and Enhances Speed and Level of Human Microglia Engraftment in the Brains of NSG Mice

Antibody Drug Conjugates Targeted to CD45 or CD117 Enable Allogeneic Hematopoietic Stem Cell Transplantation in Animal Models

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only